Heart and Vascular Institute, Center for the Diagnosis and Treatment of Pericardial Diseases, Cleveland Clinic, Cleveland, Ohio.
Heart Institute, Cedars Sinai Medical Center, Los Angeles, California.
JACC Cardiovasc Imaging. 2017 Nov;10(11):1337-1346. doi: 10.1016/j.jcmg.2016.10.020. Epub 2017 Mar 15.
The aim of this study was to evaluate the prognostic value of quantitative assessment of pericardial delayed hyperenhancement (DHE) among patients with recurrent pericarditis (RP).
Pericardial DHE on cardiac magnetic resonance may persist beyond the acute phase of pericarditis, suggesting continued pericardial inflammation.
This is a retrospective cohort study of 159 patients with RP who underwent DHE imaging and had a follow-up period of more than 6 months. Pericardial inflammation was quantified on short-axis DHE sequences by contouring the pericardium, selecting normal septal myocardium as a reference region, and then quantifying the pericardial signal that was >6 SD above the reference. Our primary outcome was clinical remission; secondary outcomes were time to recurrence and recurrence rate.
The mean age of our patients was 46 ± 14 years, and 52% were women. During a median follow-up period of 23 months (interquartile range: 15 to 34 months), 32 (20%) patients achieved clinical remission. In the multivariable Cox proportional hazards model, lower quantitative pericardial DHE (hazard ratio: 0.77; 95% confidence interval: 0.64 to 0.93; p = 0.008) was independently associated with clinical remission. When added to background clinical and laboratory variables, quantitative pericardial DHE had incremental prognostic value over baseline clinical and laboratory variables (integrated discrimination improvement: 8%; net reclassification improvement: 36%). Furthermore, patients with a higher quantitative DHE had shorter time to subsequent recurrence (p = 0.012) and had a higher recurrence rate at 6 months (p = 0.026).
Quantitative assessment of pericardial DHE was associated with clinical outcomes among patients with RP and provided incremental information regarding the clinical course of patients with RP.
本研究旨在评估复发性心包炎(RP)患者心包延迟钆增强(DHE)定量评估的预后价值。
心脏磁共振上心包 DHE 可能在心包炎的急性期后持续存在,提示心包持续炎症。
这是一项回顾性队列研究,纳入了 159 例 RP 患者,这些患者进行了 DHE 成像,随访时间超过 6 个月。在短轴 DHE 序列上心包炎症通过勾画心包、选择正常间隔心肌作为参考区域,并定量测量超过参考值 6 个标准差的心包信号进行量化。主要转归为临床缓解;次要转归为复发时间和复发率。
患者的平均年龄为 46 ± 14 岁,52%为女性。在中位数为 23 个月(四分位距:15 至 34 个月)的随访期间,32 例(20%)患者达到临床缓解。在多变量 Cox 比例风险模型中,较低的心包定量 DHE(风险比:0.77;95%置信区间:0.64 至 0.93;p = 0.008)与临床缓解独立相关。当加入背景临床和实验室变量后,心包定量 DHE 比基线临床和实验室变量具有更高的预后价值(综合鉴别改善:8%;净重新分类改善:36%)。此外,心包定量 DHE 较高的患者随后复发的时间更短(p = 0.012),并且在 6 个月时复发率更高(p = 0.026)。
心包 DHE 的定量评估与 RP 患者的临床结局相关,并提供了关于 RP 患者临床病程的额外信息。